Share on StockTwits

Cynosure (NASDAQ:CYNO) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a research note issued on Tuesday. The firm currently has a $21.70 price target on the stock. Zacks‘s price target points to a potential upside of 5.70% from the stock’s previous close.

Shares of Cynosure (NASDAQ:CYNO) traded down 2.98% on Tuesday, hitting $20.53. The stock had a trading volume of 330,324 shares. Cynosure has a 52-week low of $19.00 and a 52-week high of $31.48. The stock’s 50-day moving average is $21.35 and its 200-day moving average is $25.61. The company’s market cap is $458.2 million.

Cynosure (NASDAQ:CYNO) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.19 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.23 by $0.04. The company had revenue of $62.00 million for the quarter, compared to the consensus estimate of $64.70 million. During the same quarter last year, the company posted $0.12 earnings per share. Cynosure’s revenue was up 52.3% compared to the same quarter last year. On average, analysts predict that Cynosure will post $1.26 earnings per share for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at TheStreet downgraded shares of Cynosure from a “buy” rating to a “hold” rating in a research note on Thursday, May 8th. Analysts at Maxim Group cut their price target on shares of Cynosure from $39.00 to $35.00 in a research note on Wednesday, May 7th. They now have a “buy” rating on the stock. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $32.93.

Cynosure Inc (NASDAQ:CYNO) develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair rejuvenate the skin through the treatment of vascular and pigmented lesions, remove multi-colored tattoos, liquefy and remove unwanted fat through laser lypolysis, reduce cellulite and treat onychomycosis.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.